Pharmacopeia, Inc. and GlaxoSmithKline Collaboration Identifies Sixth Lead Compound

PRINCETON, N.J., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Pharmacopeia (Nasdaq:PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that it has identified a new lead for advancement in its alliance with GlaxoSmithKline (NYSE:GSK), through its collaboration with the Center of Excellence for External Drug Discovery (CEEDD). This newly identified lead compound is from a program being evaluated as a potential treatment for inflammatory pain and is the sixth lead compound identified through the collaboration. As a result of this success, Pharmacopeia received a $500,000 milestone payment from GSK.